{'fraction_non_alphanumeric': 0.026785714285714284, 'fraction_numerical': 0.008928571428571428, 'mean_word_length': 5.633136094674557, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐term physiologic T3 supplementation as an adjunct therapy in hypertensive heart disease

Re‐expression of the fetal gene phenotype in hypothyroidism and hypertension suggest low cardiac thyroid hormone (TH) levels during hypertension. Short‐term TH treatment in Spontaneously Hypertensive Heart Failure (SHHF) rats near heart failure is known to promote beneficial remodeling. The current study examined the effects of long‐term T3 treatment in SHHF rats. SHHF rats were treated with a physiological oral T3 dosage (4ìg/kg/day) from 12–24 months of age. SHHF rats had a decline in serum free TH levels and cardiac tissue T3 levels, cardiac dysfunction, and elevated LV collagen content compared to normotensive controls. Normalization of serum and cardiac tissue TH levels in T3 treated rats normalized heart rate, LV end‐systolic diameter, fractional shortening, systolic wall stress, and LV collagen levels. Improvements in LV end‐systolic pressure, maximal rate of pressure development and decline, and time constant of isovolumic relaxation trended toward improvement but did not reach statistical significance.